CANCER BIOLOGICS MARKET ANALYSIS

Cancer Biologics MarketSize and Trends

Market Taxonomy:

On the basis of product, the global cancer biologics market is segmented into:

• Monoclonal Antibodies
• Naked Monoclonal Antibodies
• Conjugated Monoclonal Antibodies
  • Chemo labeled Antibodies
  • Radiolabeled Antibodies
  • Bispecific Monoclonal Antibodies
• Cytokine-Based Immunotherapy
• Cancer Vaccines
• Treatment Vaccines
• Preventive Vaccines
• CAR-T Cell Therapy
• Immune Checkpoint Inhibitors
• CTL-4 Checkpoint Inhibitor
• PD-1 & PD-L1 Checkpoint Inhibitor

On the basis of application, the global cancer biologics market is segmented into:

• Non-Small Cell Lung Cancer
• Prostate Cancer 
• Breast Cancer
• Acute Myeloid Leukemia
• Lymphoma
• Multiple Myeloma
• Ovarian Cancer
• Colorectal Cancer
• Gastric Cancers
• Others

On the basis of distribution channel, the global cancer biologics market is segmented into:

• Hospital
• Clinic
• Others

On the basis of region, the global cancer biologics market is segmented into:

• North America
• Latin America
• Europe
• Middle East
• Asia Pacific
• Africa

Global Cancer Biologics Market Drivers

The global cancer biologics market is expected to witness significant growth over the forecast period, owing to increasing approvals of biologic drug by regulatory authorities for the treatment of cancer. For instance, in 2018, the U.S Food and Drug Administration (FDA) approved blinatumomab, for the patient suffering from B-cell precursor acute lymphoblastic leukemia, which show reduction in the severity of the disease, as the minimal residual disease (MRD) is found to be greater than or equal to 0.1%. Furthermore, in 2018, U.S FDA approved Cemiplimab-rwlc, for the treatment metastatic advanced stage cutaneous squamous cell cancer. The recommended Cemiplimab-rwlc dose for the patient is 350 mg, which is administrated as intravenous infusion over 30 minutes, in every three weeks.

Moreover, in January 2020, F. Hoffmann-La Roche AG announced about its submission of supplemental biological license to U.S Food and Drug Administration (FDA) for Tecentriq (atezolizumab), in combination with Avastin (bevacizumab) drug for most common form of liver cancer. Therefore, increasing number of regulatory approvals of biologic drug for the treatment of cancer, is expected to boost of cancer biologics market growth over the forecast period.